Charles Schwab
KNTE

Charles Schwab’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Charles Schwab’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-92,267
Closed -$280K – 3656
2023
Q2 		$280K Sell
92,267
-48,737
-35% -$188K ﹤0.01% 3249
2023
Q1 		$881K Sell
141,004
-8,047
-5% -$49K ﹤0.01% 2776
2022
Q4 		$909K Buy
149,051
+2,257
+2% +$18.4K ﹤0.01% 2802
2022
Q3 		$1.75M Buy
146,794
+3,269
+2% +$42.8K ﹤0.01% 2618
2022
Q2 		$1.81M Buy
143,525
+11,241
+8% +$105K ﹤0.01% 2599
2022
Q1 		$1.49M Sell
132,284
-2,486
-2% -$27.4K ﹤0.01% 2735
2021
Q4 		$2.39M Buy
134,770
+1,432
+1% +$30.2K ﹤0.01% 2641
2021
Q3 		$3.07M Buy
133,338
+43,288
+48% +$942K ﹤0.01% 2596
2021
Q2 		$2.1M Buy
90,050
+1,409
+2% +$35.8K ﹤0.01% 2701
2021
Q1 		$2.76M Buy
+88,641
New +$3.09M ﹤0.01% 2559

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Charles Schwab's KNTE Position: Q3 2023 in Review

Charles Schwab sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q3 2023, closing a stake of 92,267 shares — an estimated $280K sold.

Charles Schwab first reported a position in KNTE in Q1 2021 and held it in 10 quarters. The position peaked at $3.07M in Q3 2021. 58 funds tracked by Wall St. Rank hold KNTE as of Q3 2023.

  • Charles Schwab reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Charles Schwab sold 92,267 Kinnate Biopharma Inc. Common Stock shares in Q3 2023, an estimated $280K.
  • Charles Schwab first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2021 and held it in 10 quarters.
  • Charles Schwab's Kinnate Biopharma Inc. Common Stock position peaked at $3.07M in Q3 2021.
  • 58 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q3 2023.

Based on Charles Schwab's 13F filing for Q3 2023, filed 8 Nov 2023.